Apollomics (APLM)
Develops vebreltinib and other oncology candidates through global trials and territorial partnerships.
$27.20
Pre-market−0.15 (−0.55%)
At close$27.35(+1.52%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions4 holders · as of Mar 31, 2026 | 0.03% | 590 shares | |
| Insiders8 holders · as of Aug 24, 2026 | 74.81% | 1.64M shares | |
| Otherremainder | 25.16% | 552.6K shares |
2.20M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
4 holders · 590 shares · 1 new position · 2 increased · 0 reduced · 1 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Citigroup Inc | 438 | 0.02% | +438new | May 11, 2026 |
| UBS Group AG | 142 | 0.01% | +78 | May 5, 2026 |
| Sbi Securities Co., Ltd. | 9 | 0.00% | 0 | Apr 28, 2026 |
| BlackRock, Inc. | 1 | 0.00% | 0 | May 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Hung-Wen Chenincl. King Regent Management Limited | 49.76% | 1.45M | 13D | Aug 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Yi-Kuei Chendirector, officer: Chief Operating Officer | Purchase | 20,000 | $15.00 | 121,248 |
| Aug 14, 2026 | Peter Kuan-How Linofficer: Chief Financial Officer | Purchase | 26,667 | $15.00 | 48,979 |
| Aug 14, 2026 | Hung-Wen Chendirector, officer: Chief Executive Officer | Purchase · 3 lots | 536,667 | $14.07 | 1,448,029 |
CongressHouse and Senate disclosures
Not reported.